IONIS PHARMACEUTICALS INC
For the period ended Jun 30, 2025. Filed Jul 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 30, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
ITEM 5.
OTHER INFORMATION
Trading Plans
During the quarter ended June 30, 2025, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act), or Section 16 officers and directors, adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted in the table below.
- Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
** "Non-Rule 10b5-1 trading arrangement" as defined in item 408(c) of Regulation S-K under the Exchange Act.
| Trading Arrangement | |||||
|---|---|---|---|---|---|
| Action · Date · Rule 10b5-1* · Non-Rule 10b5-1** · Total Shares To Be Sold · Expiration Date | |||||
| Frank Bennett, EVP, Chief Scientific Officer | Termination | May 6, 2025 | X | 104,079 | Upon the execution of all instructions included in the plan |
| Joseph Baroldi, EVP, Chief Business Officer | Adoption | May 2, 2025 | X | 87,874 | The earlier to occur of (i) August 3, 2026, and (ii) Upon the execution of all instructions provided in the plan |
| Patrick O' Neil, EVP, Chief Legal Officer and General Counsel | Adoption | May 2, 2025 | X | 237,477 | The earlier to occur of (i) August 3, 2026, and (ii) Upon the execution of all instructions provided in the plan |
| Eugene Schneider, EVP, Chief Clinical Development and Operations Officer | Adoption | May 2, 2025 | X | 38,756 | The earlier to occur of (i) August 3, 2026, and (ii) Upon the execution of all instructions provided in the plan |
| Richard Geary, EVP, Chief Development Officer | Adoption | May 6, 2025 | X | 220,870 | The earlier to occur of (i) July 31, 2026, and (ii) Upon the execution of all instructions provided in the plan |
| B. Lynne Parshall, Board Member | Adoption | May 6, 2025 | X | 41,993 | The earlier to occur of (i) May 31, 2026, and (ii) Upon the execution of all instructions provided in the plan |
| Frank Bennett, EVP, Chief Scientific Officer | Adoption | May 13, 2025 | X | 67,800 | The earlier to occur of (i) August 17, 2026, and (ii) Upon the execution of all instructions provided in the plan |
Index
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.